Welcome to our dedicated page for Halozyme Therapeutics news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Therapeutics stock.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company headquartered in San Diego, CA, focused on developing and commercializing innovative oncology therapies. The company's core mission is to enhance the efficacy of cancer treatments by targeting the tumor microenvironment, particularly through its lead investigational drug, pegph20. This drug aims to improve the penetration of co-administered cancer therapies into solid tumors, potentially making existing treatments more effective.
Halozyme's proprietary ENHANZE® drug delivery technology platform has garnered significant attention and partnerships with leading pharmaceutical companies such as Roche, Pfizer, Janssen, Baxalta, AbbVie, and Lilly. This technology facilitates the subcutaneous administration of biologics and small molecule compounds that are traditionally delivered intravenously, potentially allowing for quicker and more convenient therapy delivery.
The company has built a strong foundation of value-driving partnerships and continues to innovate in drug-device combination products using advanced auto-injector technology to improve patient convenience, comfort, and adherence. Halozyme's commercial portfolio includes proprietary products like Hylenex® and XYOSTED®, and ongoing product development in partnership with pharmaceutical companies such as Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Recent achievements highlight Halozyme’s growth and innovation. Notably, the U.S. FDA approved Takeda’s HYQVIA®, co-formulated with ENHANZE®, for the maintenance therapy of chronic inflammatory demyelinating polyneuropathy (CIDP), underscoring the potential of Halozyme’s technology to enhance treatment efficacy. Another milestone includes the Japanese Ministry of Health's approval of argenx's VYVDURA® for generalized myasthenia gravis, demonstrating global expansion and acceptance of ENHANZE®-enabled treatments.
Financially, Halozyme continues to show robust growth. The company reported strong revenue and earnings growth in the first quarter of 2024, reaffirming its positive financial guidance for the year. Halozyme also announced a new $750 million share repurchase program, indicating confidence in sustained growth.
Halozyme's efforts in maintaining an extensive patent portfolio, including the recent grant of European Patent No. 4269578 for its ENHANZE® rHuPH20 product, further solidify its market position and prospects for long-term revenue durability. The company's strategic collaborations and commitment to innovative patient solutions make it a significant player in the biopharmaceutical industry.
Halozyme Therapeutics reported Q3 2021 financial results, with revenues reaching $115.8 million, up 77% year-over-year, driven by a 145% increase in royalty revenue. The company expects full-year royalty revenue to more than double from 2020. Operating income rose to $75.6 million from $40.3 million in Q3 2020. Q3 net income surged to $216.6 million, influenced by a $142.5 million tax benefit. Halozyme also repurchased 4.4 million shares for $189.7 million through Q3. Revenue guidance for 2021 is now set between $430 million and $445 million.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host its Q3 2021 financial update on November 2 at 4:30 p.m. ET. CEO Dr. Helen Torley will lead the call, following the release of Q3 financial results for the period ending September 30, 2021. Interested investors can register for the call via Halozyme's website. The company's innovative ENHANZE® technology has aided over 500,000 patients through collaborations with leading pharmaceutical firms, enhancing treatment efficiency. A recording will be available post-call for those unable to attend.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that its CFO, Elaine Sun, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 1:20 p.m. ET. An audio-only link for the presentation will be available in the "Investors" section of the Halozyme website, with a recording accessible for six months post-event. Halozyme specializes in biopharmaceutical solutions to enhance patient experiences and outcomes, leveraging its ENHANZE® technology to reduce treatment times significantly. The company's partnerships with major pharmaceutical firms play a key role in its growth.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will have Dr. Helen Torley, CEO, present at the Wells Fargo 2021 Virtual Healthcare Conference on September 10, 2021, at 10:40 a.m. ET. An audio link to the presentation will be available on Halozyme's website, with a recording accessible for six months post-event. Halozyme specializes in biopharmaceuticals, aiming to enhance patient experiences through innovative solutions like the ENHANZE® technology, drastically reducing treatment times. The company collaborates with major pharmaceutical firms, providing its technology across global markets.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported strong financial results for Q2 2021, with revenue reaching $136.5 million, up from $55.2 million in Q2 2020, largely driven by $60 million in milestone revenues. The company announced a collaboration with ViiV Healthcare for its ENHANZE® technology, raising its 2021 revenue guidance to $425-$445 million. The net income for Q2 was $91.5 million, reflecting significant growth. Additionally, Halozyme repurchased 1 million shares for $48.8 million during the quarter, enhancing shareholder value.
Halozyme Therapeutics (NASDAQ: HALO) will be represented by Elaine Sun, CFO, in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 3:30 p.m. ET. The event will be accessible via an audio link on the company's website, with a recording available for six months. Halozyme focuses on biopharmaceuticals, utilizing its ENHANZE technology to improve treatment delivery, impacting over 500,000 patients through partnerships with major pharmaceuticals.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host its second quarter 2021 conference call on August 9 at 4:30 p.m. ET. The call will be led by CEO Dr. Helen Torley and will follow the release of financial results for the quarter ending June 30, 2021. Investors can register via a provided link, and the event will be webcast live on Halozyme's corporate site. Halozyme's technology aims to enhance patient experiences, with its solutions impacting over 500,000 patients globally through multiple commercialized products.
Halozyme Therapeutics (NASDAQ: HALO) announced that Janssen Biotech has received FDA approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone for treating adults with multiple myeloma after prior therapy. This marks the sixth indication for DARZALEX FASPRO® in multiple myeloma treatment. The approval is backed by positive results from the Phase 3 APOLLO study, highlighting improved progression-free survival. Halozyme's ENHANZE® drug delivery technology underpins this therapy, enhancing patient treatment experiences through subcutaneous delivery.
Halozyme Therapeutics (NASDAQ: HALO) announced that the European Commission granted Janssen Pharmaceutical marketing authorizations for the subcutaneous formulation of daratumumab, known as DARZALEX® SC. This includes an authorization for treating adults with newly diagnosed systemic light-chain amyloidosis (first approved therapy for AL amyloidosis in Europe) and for adults with multiple myeloma who are lenalidomide refractory. These approvals enhance treatment options for specific patient groups in Europe, furthering Halozyme's commitment to improving patient outcomes.
ViiV Healthcare and Halozyme Therapeutics have entered a global collaboration that grants ViiV exclusive access to Halozyme's ENHANZE® drug delivery technology for HIV treatments. ViiV will pay $40 million upfront, with potential milestone payments totaling up to $175 million per target. This partnership aims to enhance the development of long-acting HIV therapies, reducing the frequency of medication. The PH20 enzyme allows for efficient large-volume subcutaneous injections, potentially addressing treatment challenges for patients and improving their experience.
FAQ
What is the current stock price of Halozyme Therapeutics (HALO)?
What is the market cap of Halozyme Therapeutics (HALO)?
What is Halozyme Therapeutics' main focus?
What is the ENHANZE® technology?
Who are Halozyme's key partners?
What recent approvals have Halozyme's technologies received?
What are some of Halozyme's proprietary products?
Where is Halozyme headquartered?
How does Halozyme's ENHANZE® technology benefit patients?
What is the significance of Halozyme's recent European patent grant?
What financial outlook did Halozyme recently provide?
What is pegph20?
